Molecular Basis for the Unique Deubiquitinating Activity of the NF-κB Inhibitor A20

Journal of Molecular Biology

Volumn 376, Issue 2, 2008, Pages 526-540

  Lin, Su Chang ^a   Chung, Jee Y ^a   Lamothe, Betty ^b   Rajashankar, Kanagalaghatta ^c   Lu, Miao ^a   Lo, Yu Chih ^a   Lam, Amy Y ^a   Darnay, Bryant G ^b   Wu, Hao ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c ARGONNE NATIONAL LABORATORY   (United States)

Author keywords

A20; crystal structure; deubiquitination; DUB; TRAF6

Indexed keywords

I KAPPA B; INTERLEUKIN 1; LYSINE; NUCLEAR FACTOR KAPPA B INHIBITOR A20; TOLL LIKE RECEPTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CONTROLLED STUDY; CRYSTALLOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE;

EID: 38549146936     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.11.092     Document Type: Article

References (66)

1. Jaattela M., Mouritzen H., Elling F., and Bastholm L. A20 zinc finger protein inhibits TNF and IL-1 signaling. J. Immunol. 156 (1996) 1166-1173
2. Cooper J.T., Stroka D.M., Brostjan C., Palmetshofer A., Bach F.H., and Ferran C. A20 blocks endothelial cell activation through a NF-kappaB-dependent mechanism. J. Biol. Chem. 271 (1996) 18068-18073
3. Ferran C., Stroka D.M., Badrichani A.Z., Cooper J.T., and Bach F.H. Adenovirus-mediated gene transfer of A20 renders endothelial cells resistant to activation: a means of evaluating the role of endothelial cell activation in xenograft rejection. Transplant. Proc. 29 (1997) 879-880
4. Grey S.T., Arvelo M.B., Hasenkamp W., Bach F.H., and Ferran C. A20 inhibits cytokine-induced apoptosis and nuclear factor kappaB-dependent gene activation in islets. J. Exp. Med. 190 (1999) 1135-1146
5. Beyaert R., Heyninck K., and Van Huffel S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem. Pharmacol. 60 (2000) 1143-1151
6. O'Reilly S.M., and Moynagh P.N. Regulation of Toll-like receptor 4 signalling by A20 zinc finger protein. Biochem. Biophys. Res. Commun. 303 (2003) 586-593
7. Dixit V.M., Green S., Sarma V., Holzman L.B., Wolf F.W., O'Rourke K., et al. Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J. Biol. Chem. 265 (1990) 2973-2978
8. Opipari Jr. A.W., Boguski M.S., and Dixit V.M. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J. Biol. Chem. 265 (1990) 14705-14708
9. Krikos A., Laherty C.D., and Dixit V.M. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J. Biol. Chem. 267 (1992) 17971-17976
10. Laherty C.D., Hu H.M., Opipari A.W., Wang F., and Dixit V.M. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J. Biol. Chem. 267 (1992) 24157-24160
11. Laherty C.D., Perkins N.D., and Dixit V.M. Human T cell leukemia virus type I Tax and phorbol 12-myristate 13-acetate induce expression of the A20 zinc finger protein by distinct mechanisms involving nuclear factor kappa B. J. Biol. Chem. 268 (1993) 5032-5039
12. Tewari M., Wolf F.W., Seldin M.F., Shea O.'K.S., Dixit V.M., and Turka L.A. Lymphoid expression and regulation of A20, an inhibitor of programmed cell death. J. Immunol. 154 (1995) 1699-1706
13. Sarma V., Lin Z., Clark L., Rust B.M., Tewari M., Noelle R.J., and Dixit V.M. Activation of the B-cell surface receptor CD40 induces A20, a novel zinc finger protein that inhibits apoptosis. J. Biol. Chem. 270 (1995) 12343-12346
14. Hu X., Yee E., Harlan J.M., Wong F., and Karsan A. Lipopolysaccharide induces the antiapoptotic molecules, A1 and A20, in microvascular endothelial cells. Blood 92 (1998) 2759-2765
15. Durkop H., Hirsch B., Hahn C., Foss H.D., and Stein H. Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation. J. Pathol. 200 (2003) 229-239
16. Lee E.G., Boone D.L., Chai S., Libby S.L., Chien M., Lodolce J.P., and Ma A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289 (2000) 2350-2354
17. Boone D.L., Turer E.E., Lee E.G., Ahmad R.C., Wheeler M.T., Tsui C., et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat. Immunol. 5 (2004) 1052-1060
18. Lin R., Yang L., Nakhaei P., Sun Q., Sharif-E. Askari I., and Julkunen J. Negative regulation of the retinoic acid-inducible gene I-induced antiviral state by the ubiquitin-editing protein A20. J. Biol. Chem. 281 (2006) 2095-2103
19. Wang Y.Y., Li L., Han K.J., Zhai Z., and Shu H.B. A20 is a potent inhibitor of TLR3- and Sendai virus-induced activation of NF-kappaB and ISRE and IFN-beta promoter. FEBS Lett. 576 (2004) 86-90
20. Saitoh T., Yamamoto M., Miyagishi M., Taira K., Nakanishi M., Fujita T., et al. A20 is a negative regulator of IFN regulatory factor 3 signaling. J. Immunol. 174 (2005) 1507-1512
21. Hayden M.S., and Ghosh S. Signaling to NF-kappaB. Genes Dev. 18 (2004) 2195-2224
22. Heyninck K., and Beyaert R. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level of TRAF6. FEBS Lett. 442 (1999) 147-150
23. Heyninck K., De Valck D., Vanden Berghe W., Van Criekinge W., Contreras R., Fiers W., et al. The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J. Cell Biol. 145 (1999) 1471-1482
24. Wertz I.E., O'Rourke K.M., Zhou H., Eby M., Aravind L., Seshagiri S., et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430 (2004) 694-699
25. Zhang S.Q., Kovalenko A., Cantarella G., and Wallach D. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity 12 (2000) 301-311
26. Chen Z.J. Ubiquitin signalling in the NF-kappaB pathway. Nat. Cell Biol. 7 (2005) 758-765
27. Deng L., Wang C., Spencer E., Yang L., Braun A., You J., et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103 (2000) 351-361
28. Wang C., Deng L., Hong M., Akkaraju G.R., Inoue J., and Chen Z.J. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412 (2001) 346-351
29. Lamothe B., Besse A., Campos A.D., Webster W.K., Wu H., and Darnay B.G. Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of I kappa B kinase activation. J. Biol. Chem. 282 (2007) 4102-4112
30. Ninomiya-Tsuji J., Kishimoto K., Hiyama A., Inoue J., Cao Z., and Matsumoto K. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 398 (1999) 252-256
31. Holtmann H., Enninga J., Kalble S., Thiefes A., Dorrie A., Broemer M., et al. The MAPK kinase kinase TAK1 plays a central role in coupling the interleukin-1 receptor to both transcriptional and RNA-targeted mechanisms of gene regulation. J. Biol. Chem. 276 (2001) 3508-3516
32. Irie T., Muta T., and Takeshige K. TAK1 mediates an activation signal from toll-like receptor(s) to nuclear factor-kappaB in lipopolysaccharide-stimulated macrophages. FEBS Lett. 467 (2000) 160-164
33. Lee J., Mira-Arbibe L., and Ulevitch R.J. TAK1 regulates multiple protein kinase cascades activated by bacterial lipopolysaccharide. J. Leukocyte Biol. 68 (2000) 909-915
34. Jiang Z., Zamanian-Daryoush M., Nie H., Silva A.M., Williams B.R., and Li X. Poly(I-C)-induced Toll-like receptor 3 (TLR3)-mediated activation of NFkappa B and MAP kinase is through an interleukin-1 receptor-associated kinase (IRAK)-independent pathway employing the signaling components TLR3-TRAF6-TAK1-TAB2-PKR. J. Biol. Chem. 278 (2003) 16713-16719
35. Mizukami J., Takaesu G., Akatsuka H., Sakurai H., Ninomiya-Tsuji J., Matsumoto K., and Sakurai N. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol. Cell Biol. 22 (2002) 992-1000
36. Shibuya H., Yamaguchi K., Shirakabe K., Tonegawa A., Gotoh Y., Ueno N., et al. TAB1: an activator of the TAK1 MAPKKK in TGF-beta signal transduction. Science 272 (1996) 1179-1182
37. Takaesu G., Kishida S., Hiyama A., Yamaguchi K., Shibuya H., Irie K., et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol. Cell 5 (2000) 649-658
38. Ishitani T., Takaesu G., Ninomiya-Tsuji J., Shibuya H., Gaynor R.B., and Matsumoto K. Role of the TAB2-related protein TAB3 in IL-1 and TNF signaling. EMBO J. 22 (2003) 6277-6288
39. Cheung P.C., Nebreda A.R., and Cohen P. TAB3, a new binding partner of the protein kinase TAK1. Biochem. J. 378 (2004) 27-34
40. Jin G., Klika A., Callahan M., Faga B., Danzig J., Jiang Z., et al. Identification of a human NF-{kappa}B-activating protein, TAB3. Proc. Natl Acad. Sci. USA 101 (2004) 2028-2033
41. Besse A., Lamothe B., Campos A.D., Webster W.K., Maddineni U., Lin S.C., et al. TAK1-dependent signaling requires functional interaction with TAB2/TAB3. J. Biol. Chem. 282 (2007) 3918-3928
42. Kanayama A., Seth R.B., Sun L., Ea C.K., Hong M., Shaito A., et al. TAB2 and TAB3 activate the NF-kappaB pathway through binding to polyubiquitin chains. Mol. Cell 15 (2004) 535-548
43. Heyninck K., and Beyaert R. A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions. Trends Biochem. Sci. 30 (2005) 1-4
44. Evans P.C., Ovaa H., Hamon M., Kilshaw P.J., Hamm S., Bauer S., et al. Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem. J. 378 (2004) 727-734
45. Klinkenberg M., Van Huffel S., Heyninck K., and Beyaert R. Functional redundancy of the zinc fingers of A20 for inhibition of NF-kappaB activation and protein-protein interactions. FEBS Lett. 498 (2001) 93-97
46. Amerik A.Y., and Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim. Biophys. Acta 1695 (2004) 189-207
47. Nijman S.M., Luna-Vargas M.P., Velds A., Brummelkamp T.R., Dirac A.M., Sixma T.K., and Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell 123 (2005) 773-786
48. Makarova K.S., Aravind L., and Koonin E.V. A novel superfamily of predicted cysteine proteases from eukaryotes, viruses and Chlamydia pneumoniae. Trends Biochem. Sci. 25 (2000) 50-52
49. Yeates T.O. Detecting and overcoming crystal twinning. Methods Enzymol. 276 (1997) 344-358
50. Lee S., Sawaya M.R., and Eisenberg D. Structure of superoxide dismutase from Pyrobaculum aerophilum presents a challenging case in molecular replacement with multiple molecules, pseudo-symmetry and twinning. Acta Crystallogr. Sect. D 59 (2003) 2191-2199
51. Evans P.C., Taylor E.R., Coadwell J., Heyninck K., Beyaert R., and Kilshaw P.J. Isolation and characterization of two novel A20-like proteins. Biochem. J. 357 (2001) 617-623
52. Johnston S.C., Riddle S.M., Cohen R.E., and Hill C.P. Structural basis for the specificity of ubiquitin C-terminal hydrolases. EMBO J. 18 (1999) 3877-3887
53. Misaghi S., Galardy P.J., Meester W.J., Ovaa H., Ploegh H.L., and Gaudet R. Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J. Biol. Chem. 280 (2005) 1512-1520
54. Hu M., Li P., Li M., Li W., Yao T., Wu J.W., et al. Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell 111 (2002) 1041-1054
55. Hu M., Li P., Song L., Jeffrey P.D., Chenova T.A., Wilkinson K.D., et al. Structure and mechanisms of the proteasome-associated deubiquitinating enzyme USP14. EMBO J. 24 (2005) 3747-3756
56. Renatus M., Parrado S.G., D'Arcy A., Eidhoff U., Gerhartz B., Hassiepen U., et al. Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure 14 (2006) 1293-1302
57. Nanao M.H., Tcherniuk S.O., Chroboczek J., Dideberg O., Dessen A., and Balakirev M.Y. Crystal structure of human otubain 2. EMBO Rep. 5 (2004) 783-788
58. King R.C., and Storto P.D. The role of the otu gene in Drosophila oogenesis. Bioessays 8 (1988) 18-24
59. Rawlings N.D., O'Brien E., and Barrett A.J. MEROPS: the protease database. Nucleic Acids Res. 30 (2002) 343-346
60. Hershko A., and Rose I.A. Ubiquitin-aldehyde: a general inhibitor of ubiquitin-recycling processes. Proc. Natl Acad. Sci. USA 84 (1987) 1829-1833
61. Borodovsky A., Ovaa H., Kolli N., Gan-Erdene T., Wilkinson K.D., Ploegh H.L., and Kessler B.M. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9 (2002) 1149-1159
62. Pickart C.M., and Rose I.A. Mechanism of ubiquitin carboxyl-terminal hydrolase. Borohydride and hydroxylamine inactivate in the presence of ubiquitin. J. Biol. Chem. 261 (1986) 10210-10217
63. Dang L.C., Melandri F.D., and Stein R.L. Kinetic and mechanistic studies on the hydrolysis of ubiquitin C-terminal 7-amido-4-methylcoumarin by deubiquitinating enzymes. Biochemistry 37 (1998) 1868-1879
64. Hochrainer K., and Lipp J. Ubiquitylation within signaling pathways in- and outside of inflammation. Thromb. Haemost. 97 (2007) 370-377
65. Komander D., and Barford D. Structure of the A20 OTU domain and mechanistic insights into deubiquitination. Biochem J. 409 (2008) 77-85
66. Padilla J.E., and Yeates T.O. A statistic for local intensity differences: robustness to anisotropy and pseudo-centering and utility for detecting twinning. Acta Crystallogr. Sect. D 59 (2003) 1124-1130